InMed Pharmaceuticals Inc. (INM) Tops Q2 EPS by 4c

InMed Pharmaceuticals Inc. (NASDAQ: INM) reported Q2 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $1.24 million versus the consensus estimate of $1.13 million.

For earnings history and earnings-related data on InMed Pharmaceuticals Inc. (INM) click here.

You May Also Be Interested In

• SLM (SLM) Misses Q2 EPS by 16c; offers guidance
• Alpine Income Property Trust, Inc. (PINE) Tops Q2 EPS by 2c; Offers Guidance
• BayCom Corp (BCML) Misses Q2 EPS by 128c